BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12

• Press Releases

  Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

  January 12, 2026

   · 

  4 min read
• Press Releases

  Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

  January 12, 2026

   · 

  5 min read
• Press Releases

  Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

  January 12, 2026

   · 

  6 min read
• Press Releases

  West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

  January 12, 2026

   · 

  4 min read
• Press Releases

  AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

  January 12, 2026

   · 

  4 min read
• Press Releases

  Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

  January 12, 2026

   · 

  10 min read
• Press Releases

  Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

  January 12, 2026

   · 

  10 min read
• Press Releases

  BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

  January 12, 2026

   · 

  13 min read
• Press Releases

  Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance

  January 12, 2026

   · 

  8 min read
• Press Releases

  Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

  January 12, 2026

   · 

  6 min read